IP Library Granted Patent US 9,695,220
Granted Patent B2
US 9,695,220 · App. 15/095,856 · Granted Jul 4, 2017

Methods of predicting ancestral virus sequences and uses thereof

Inventors: Luk H. Vandenberghe (Weston, MA); Eric Zinn (Brighton, MA)
Assignees: Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute
C07K14/005A61K39/00C07K14/00C12N7/00C12N15/86A61K2039/525A61K2039/6075C12N2750/14121C12N2750/14122C12N2750/14141C12N2750/14142C12N2750/14143C12N2750/14171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,695,220
App. No.
15/095,856
Granted
Jul 4, 2017
Kind
B2
Abstract

Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.

Claims (11)

1. An adeno-associated virus (AAV) capsid polypeptide having the amino acid sequence shown in SEQ ID NO: 1.

2. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide:

exhibits a lower seroprevalence than does an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide exhibit about the same or a lower seroprevalence than does an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide; and/or

are neutralized to a lesser extent by human serum than is an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide is neutralized to a similar or lesser extent by human serum than is an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide.

3. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide is purified.

4. The AAV capsid polypeptide of claim 1 , encoded by the nucleic acid sequence shown in SEQ ID NO: 2.

5. A nucleic acid molecule encoding an adeno-associated virus (AAV) capsid polypeptide having the nucleic acid sequence shown in SEQ ID NO: 2.

6. A vector comprising the nucleic acid molecule of claim 5 .

7. An isolated host cell comprising the vector of claim 6 .

8. A purified virus particle comprising the AAV capsid polypeptide of claim 1 .

9. The purified virus particle of claim 8 , further comprising a transgene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: VANDENBERGHE, LUK H.
To: MASSACHUSETTS EYE & EAR INFIRMARY
Reel/Frame 041127/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: ZINN, ERIC
To: SCHEPENS EYE RESEARCH INSTITUTE
Reel/Frame 041127/0597 →
Continuity (3)
Continuation In Part PCTUS2014060163 · Oct 10, 2014
Provisional Application 61889827 · Oct 11, 2013
Related Publication 20160215024A1 · Jul 28, 2016